PARIS, July 08, 2026--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates.
Cash Position as of June 30, 2026
GenSight Biologics' cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.
The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as well as the preparation of the Phase III RECOVER study for GS010, GenSight's gene therapy for Leber Hereditary Optic Neuropathy (LHON).1
Proceeds from Early Access Programs
During the first half of 2026, the Company collected €6.8 million in cash proceeds from its early access Programs, of which €4.3 million was collected during the second quarter of 2026. These proceeds were received between the end of March and mid-June 2026 and include payment for the first patient treated under the Company's Paid Named Patient Program in Israel.
Following the July 2021 reform in France (Decree No. 2021-869 of June 30, 2021 on early access authorizations), companies are required to issue a rebate based on the total compensation received for early access treatments performed in France over a calendar year. The payment, which is determined based on a progressive scale, is due in November of the following year. Accordingly, the Company will pay a rebate based on proceeds received from the 2026 French Named Patient Early Access Program (AAC) in November 2027, which is expected to range from 25% to 35%.
More treatments are expected to be carried out this year under early access programs in various countries.
Business Updates
The AAC program may also be accessible to citizens of other European Union countries, not only to residents of France. In the first half of 2026, the Company treated the first patients from other European countries under the program.
During the spring of 2026, the Company continued to improve and optimize the existing manufacturing process for GS010/LUMEVOQ® at Catalent, its contract manufacturing organization. The engineering run was initiated in June. The final confirmatory tests are currently underway, and the Company expects to confirm the success of the technology transfer in the summer of 2026. Following this confirmation, GenSight will begin manufacturing the batches required to supply both the Phase III RECOVER study and its Early Access Programs. The Company currently holds more than 60 vials in inventory, which it expects to be sufficient to treat patients through the end of the first half of 2027.